Concepedia

Min H. Kang

MH

85

Publications

4.9K

Citations

41

H-Index

2001

Active since

Affiliations

Texas Tech University(Current)

Texas Tech University Health Sciences Center

St. Jude Children's Research Hospital

Children's Hospital of Philadelphia

Center for Cancer Research

Min H. Kang is an author at Texas Tech University specializing in medicine, cancer research, and tumor biology.

ORCID

Top concepts

Publications per year

2001–2022

85

Publications

85

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Victor Sandor, Susan Bakke, Robert W. Robey et al. · PubMed · 2002 · 509 citations

Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

John M. Maris, Christopher L. Morton, Richard Görlick et al. · Pediatric Blood & Cancer · 2010 · 230 citations · Full text

A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer

John L. Marshall, Naiyer A. Rizvi, John Kauh et al. · Journal of Experimental Therapeutics and Oncology · 2002 · 205 citations

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo

Min H. Kang, Yun Hee Kang, Barbara Szymanska et al. · Blood · 2007 · 155 citations · Full text

The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma

Ashujit Tagde, Harpal Singh, Min H. Kang et al. · Blood Cancer Journal · 2014 · 123 citations · Full text

Rows per page

1–5 of 85